Name: Krabbe Disease Treatment Market Size Share Growth and Report 2023-2030
Creator: DataM Intelligence
Published: Fri Oct 25 2024 14:54:52 GMT+0530 (India Standard Time)
License: https://www.datamintelligence.com/terms-conditions

Krabbe Disease Treatment Market Size Share Growth and Report 2023-2030

Krabbe Disease Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)

<h2>Krabbe Disease Treatment Market is Segmented&nbsp;By Disease Type(Infantile, Late-onset),&nbsp;By Diagnosis(Laboratory tests, Imaging tests, Genetic testing, Newborn screening, Others),&nbsp;By Treatment(Anticonvulsant Agents, Muscle Relaxer Drugs, Bone Marrow Transplantation, Stem cell transplantation, Others),&nbsp;By End-User(Hospitals, Diagnostic Centers, Clinics, Others)By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others),&nbsp;and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2023-2030</h2>

<blockquote>
Krabbe Disease Treatment Market is growing at a high CAGR 7.86% during the forecast period (2023-2030). 
</blockquote>

Krabbe disease is a life-threatening neurological disorder commonly known as globoid cell leukodystrophy. It is one of a series of conditions known as leukodystrophies, caused by the breakdown of myelin in the nervous system (demyelination). Myelin is the protective layer that surrounds nerve cells and ensures that nerve signals are transmitted quickly. Krabbe illness is also characterized by aberrant brain cells known as globoid cells, huge cells with more than one nucleus. Krabbe disease is identified in children as young as six years old, and there is presently no cure; nevertheless, the condition is controlled by supportive care.

As per DataM Intelligence, Krabbe Disease Treatment Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Krabbe Disease Treatment Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Krabbe Disease Treatment Market in the United States and Canada produces the utmost share. Whereas the European Krabbe Disease Treatment Market is projected to continue its presence globally during the period of 2022- 2029.

<h3>Krabbe Disease Treatment Market Dynamics</h3>

Advancement in the therapies for the treatment of Krabbe Disease is expected to drive market growth.

Other experimental medicines have demonstrated varying degrees of effectiveness in preclinical testing, with some of the best results from combining medications. For instance, HSCT has been used with SRT and gene therapy. The combinations consistently yield better outcomes than the matched individual therapies. Other approaches such as ERT, chaperone therapy, and anti-inflammatory therapy also have the potential to contribute as part of a combination or standalone therapies. Moreover, various clinical studies have been carried out. For instance, D-Cycloserine is an FDA-approved medicine for tuberculosis tested in numerous clinical studies for various diseases. Preliminary data suggest that it can slow disease progression in twitcher mice; consequently, D-cycloserine should be studied further to see if it can help individuals with Krabbe disease. Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

The finite patient pool for clinical trials, lack of awareness of the disease and side effects of the drugs are factors the market is expected to hamper in the forecast period.

<h3>COVID-19 Impact Analysis</h3>

The COVID-19 pandemic has moderately impacted healthcare systems and the market. The risk of severe forms of COVID-19 may be high in the rare metabolic community, where all patients, including children, experience multiorgan impairments due to their chronic condition. MetabERN, the European Reference Network for Hereditary Metabolic Diseases, conducted two surveys: one for patients&#39; organizations (PO) and the other for healthcare providers (HCPs). COVID-19 incidence was lower in the community of uncommon metabolic patients (72.9 per 100,000 vs. 117 per 100,000) than in the general European population. On the other hand, patients were subjected to significant disruptions in their care, with most appointments and treatments being canceled, curtailed, or postponed. Almost all HCPs (90 percent) used telemedicine to replace face-to-face visits, about half of patients undergoing treatment changes switched from hospital to home therapy, and a quarter of patients had difficulty getting their medications.

Additionally, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

<h3>Krabbe Disease Treatment Market Segment Analysis</h3>

Stem cell transplantation segment is expected to hold the largest market share in krabbe disease treatment market

The stem cell transplantation segment is expected to dominate in 2021. The segment benefits because if treatment begins before the development of symptoms, that is, when a diagnosis is made via a newborn screening test, this therapy may improve outcomes in newborns. According to current evidence, stem cell transplantation is most beneficial when initiated before a newborn reaches the age of two weeks. Moreover, Pre-symptomatic children who have stem cell transplantation had a slower disease progression and a better quality &mdash; and duration &mdash; of life than children who do not receive stem cell transplantation before symptoms arise, according to studies. Furthermore, This medication may also benefit older children and adults with modest Krabbe disease symptoms. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

Krabbe Disease Treatment Market

<table border="1" cellpadding="1" cellspacing="1">
	<tbody>
		<tr>
			<td>
			Metrics
			</td>
			<td>
			Details
			</td>
		</tr>
		<tr>
			<td>
			Market&nbsp;CAGR
			</td>
			<td>
			7.86%
			</td>
		</tr>
		<tr>
			<td>
			Segments Covered
			</td>
			<td>
			By Disease Type,&nbsp;By Diagnosis,&nbsp;By Treatment,&nbsp;By End-User, By&nbsp;Distribution Channel,&nbsp;and By Region
			</td>
		</tr>
		<tr>
			<td>
			Report Insights Covered
			</td>
			<td>
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
			</td>
		</tr>
		<tr>
			<td>
			Fastest Growing Region
			</td>
			<td>
			Asia Pacific
			</td>
		</tr>
		<tr>
			<td>
			Largest Market Share&nbsp;
			</td>
			<td>
			North America
			</td>
		</tr>
	</tbody>
</table>

<h3>Krabbe Disease Treatment Market Geographical Analysis</h3>

North America region holds the largest market share in the global krabbe disease treatment market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of Krabbe Disease, rising geriatric population, Rapid adoption of cutting-edge technologies and novel medications for the treatment of Krabbe illness, well-established infrastructure and increase in clinical development of the treatment for the Krabbe disease, and rise in investment in research &amp; development are some of the factors the market is expected to boost in the forecast period. For instance, the Krabbe disease affects about 1 in 100,000 people in the United States. It is also known as globoid cell leukodystrophy. Males are affected as often as females.

Also, more than two-fifths of all known cases of Krabbe disease is caused by a missense mutation in the GLC enzyme. Therapeutic approaches for other lysosomal storage diseases are ineffective in treating Krabbe disease due to the lack of accumulated primary substrate within the lysosome and the predominant CNS sickness. The molecules are being researched because they have the potential to pass the blood-brain barrier more efficiently than enzymes due to certain properties such as low molecular weight, low toxicity, and high bioavailability. Allosteric chaperones, directed away from the enzyme&#39;s active site, have also been found. Pharmacological chaperone therapy, which is expected to be effective, can be used to treat Krabbe disease. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

<h3>Key Development</h3>

For instance in March 2024, Forge Biologics, announced that the Medicines and Healthcare Products Regulatory Agency (MHRA), granted Innovation Passport designation to the Company&rsquo;s novel AAV gene therapy program, FBX-101, thus entering the Innovative Licensing and Access Pathway (ILAP). Eventually accelerating regulatory and market access interactions in the UK

<h3>Krabbe Disease Treatment Market Competitive Landscape</h3>

Major key players in the krabbe disease treatment market are Lannett, Novartis, Lundbeck, Lupin Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., Meda Pharmaceuticals Inc&nbsp;&nbsp; , Mayne Pharma Group Limited, Pfizer Inc., Schwarz Pharma, Inc, Acorda Therapeutics Inc.&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;

Pfizer Inc.:

Overview:

Pfizer Inc. is an American multinational pharmaceutical company that offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. It has a portfolio of over 150 products across 15 therapeutic areas. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.

&shy;Product Portfolio:

SKELAXIN(metaxalone): Metaxalone is a muscle relaxant. It works by blocking nerve impulses (or pain sensations) in the brain. It is used with rest and physical therapy to treat skeletal muscle conditions such as pain or injury.

<ol>
	<li>Methodology and Scope
	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>Market Definition and Overview</li>
	<li>Executive Summary
	<ol>
		<li>Market Snippet by Disease Type</li>
		<li>Market Snippet by Diagnosis</li>
		<li>Market Snippet by Treatment</li>
		<li>Market Snippet by End user</li>
		<li>Market Snippet by Distribution channel</li>
		<li>Market Snippet by Region</li>
	</ol>
	</li>
	<li>Market Dynamics
	<ol>
		<li>Market Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>Advancement in the therapies for the treatment of Krabbe Disease is expected to drive market growth.</li>
			</ol>
			</li>
			<li>Restraints:
			<ol>
				<li>Lack of awareness of the disease and side effects of the drugs are factors the market is expected to hamper in the forecast period.</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Industry Analysis
	<ol>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Unmet Needs</li>
	</ol>
	</li>
	<li>COVID-19 Analysis
	<ol>
		<li>Analysis of Covid-19 on the Market
		<ol>
			<li>Before COVID-19 Market Scenario</li>
			<li>Present COVID-19 Market Scenario</li>
			<li>After COVID-19 or Future Scenario</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid Covid-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion&nbsp;</li>
	</ol>
	</li>
	<li>By Disease Type
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type</li>
			<li>Market Attractiveness Index, By Disease Type Segment</li>
		</ol>
		</li>
		<li>Infantile*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li>
		</ol>
		</li>
		<li>Late-onset</li>
	</ol>
	</li>
	<li>By Diagnosis
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis</li>
			<li>Market Attractiveness Index, By Diagnosis Segment</li>
		</ol>
		</li>
		<li>Laboratory tests*
		<ol>
			<li>Blood Test</li>
			<li>Others</li>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li>
		</ol>
		</li>
		<li>Imaging tests
		<ol>
			<li>Magnetic resonance imaging (MRI)</li>
			<li>Computerized tomography (CT)</li>
			<li>Others</li>
		</ol>
		</li>
		<li>Genetic testing</li>
		<li>Newborn screening</li>
		<li>Others</li>
	</ol>
	</li>
	<li>By Treatment
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment</li>
			<li>Market Attractiveness Index, By Treatment Segment</li>
		</ol>
		</li>
		<li>Anticonvulsant Agents*
		<ol>
			<li>Acetazolamide</li>
			<li>Carbamazepine</li>
			<li>Tegretol</li>
			<li>Clobazam</li>
			<li>Gabapentin</li>
			<li>Others</li>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li>
		</ol>
		</li>
		<li>Muscle Relaxer Drugs
		<ol>
			<li>Tizanidine</li>
			<li>Carisoprodol</li>
			<li>Chlorzoxazone</li>
			<li>Metaxalone</li>
			<li>Others</li>
		</ol>
		</li>
		<li>Bone Marrow Transplantation</li>
		<li>Stem cell transplantation</li>
		<li>Others</li>
	</ol>
	</li>
	<li>By End user
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user</li>
			<li>Market Attractiveness Index, By End user Segment</li>
		</ol>
		</li>
		<li>Hospitals*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li>
		</ol>
		</li>
		<li>Diagnostic Centers</li>
		<li>Clinics</li>
		<li>Others</li>
	</ol>
	</li>
	<li>By Distribution Channel
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Attractiveness Index, By Distribution Channel Segment</li>
		</ol>
		</li>
		<li>Hospital Pharmacies*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li>
		</ol>
		</li>
		<li>Retail Pharmacies</li>
		<li>Online Pharmacies</li>
		<li>Others</li>
	</ol>
	</li>
	<li>By Region
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>U.K.</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution&nbsp; Channel</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Competitive Landscape
	<ol>
		<li>Key Developments and Strategies</li>
		<li>Company Share Analysis</li>
		<li>Product Benchmarking</li>
		<li>List of Key Companies to Watch</li>
	</ol>
	</li>
	<li>Company Profiles
	<ol>
		<li>Lannett*
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Key Highlights</li>
			<li>Financial Overview</li>
		</ol>
		</li>
		<li>Novartis</li>
		<li>Lundbeck</li>
		<li>Lupin Pharmaceuticals, Inc.</li>
		<li>Teva Pharmaceuticals USA, Inc.</li>
		<li>Meda Pharmaceuticals Inc</li>
		<li>Mayne Pharma Group Limited</li>
		<li>Pfizer Inc.</li>
		<li>Schwarz Pharma, Inc</li>
		<li>Acorda Therapeutics Inc(*LIST NOT EXHAUSTIVE)</li>
	</ol>
	</li>
	<li>DataM Intelligence
	<ol>
		<li>Appendix</li>
		<li>About Us and Applications</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">List of Tables &amp; Figures</h2>

List of Tables

Table1 Global Krabbe Disease Treatment Market Value, By Disease Type, 2022, 2026 &amp; 2030 ($ Million)

Table2 Global Krabbe Disease Treatment Market Value, By Diagnosis, 2022, 2026 &amp; 2030 ($ Million)

Table3 Global Krabbe Disease Treatment Market Value, By Treatment, 2022, 2026 &amp; 2030 ($ Million)

Table4 Global Krabbe Disease Treatment Market Value, By End user, 2022, 2026 &amp; 2030 ($ Million)

Table5 Global Krabbe Disease Treatment Market Value, By Distribution Channel, 2022, 2026 &amp; 2030 ($ Million)

Table6 Global Krabbe Disease Treatment Market Value, By Region, 2022, 2026 &amp; 2030 ($ Million)

Table7 Global Krabbe Disease Treatment Market Value, By Disease Type, 2022, 2026 &amp; 2030 ($ Million)

Table8 Global Krabbe Disease Treatment Market Value, By Disease Type, 2021-2030 ($ Million)

Table9 Global Krabbe Disease Treatment Market Value, By Diagnosis, 2022, 2026 &amp; 2030 ($ Million)

Table10 Global Krabbe Disease Treatment Market Value, By Diagnosis, 2021-2030 ($ Million)

Table11 Global Krabbe Disease Treatment Market Value, By Treatment, 2022, 2026 &amp; 2030 ($ Million)

Table12 Global Krabbe Disease Treatment Market Value, By Treatment, 2021-2030 ($ Million)

Table13 Global Krabbe Disease Treatment Market Value, By End user, 2022, 2026 &amp; 2030 ($ Million)

Table14 Global Krabbe Disease Treatment Market Value, By End user, 2021-2030 ($ Million)

Table15 Global Krabbe Disease Treatment Market Value, By Distribution Channel, 2022, 2026 &amp; 2030 ($ Million)

Table16 Global Krabbe Disease Treatment Market Value, By Distribution Channel, 2021-2030 ($ Million)

Table17 Global Krabbe Disease Treatment Market Value, By Region, 2022, 2026 &amp; 2030 ($ Million)

Table18 Global Krabbe Disease Treatment Market Value, By Region, 2021-2030 ($ Million)

Table19 North America Krabbe Disease Treatment Market Value, By Disease Type, 2021-2030 ($ Million)

Table20 North America Krabbe Disease Treatment Market Value, By Diagnosis, 2021-2030 ($ Million)

Table21 North America Krabbe Disease Treatment Market Value, By Treatment, 2021-2030 ($ Million)

Table22 North America Krabbe Disease Treatment Market Value, By End user, 2021-2030 ($ Million)

Table23 North America Krabbe Disease Treatment Market Value, By Distribution Channel, 2021-2030 ($ Million)

Table24 North America Krabbe Disease Treatment Market Value, By Country, 2021-2030 ($ Million)

Table25 South America Krabbe Disease Treatment Market Value, By Disease Type, 2021-2030 ($ Million)

Table26 South America Krabbe Disease Treatment Market Value, By Diagnosis, 2021-2030 ($ Million)

Table27 South America Krabbe Disease Treatment Market Value, By Treatment, 2021-2030 ($ Million)

Table28 South America Krabbe Disease Treatment Market Value, By End user, 2021-2030 ($ Million)

Table29 South America Krabbe Disease Treatment Market Value, By Distribution Channel, 2021-2030 ($ Million)

Table30 South America Krabbe Disease Treatment Market Value, By Country, 2021-2030 ($ Million)

Table31 Europe Krabbe Disease Treatment Market Value, By Disease Type, 2021-2030 ($ Million)

Table32 Europe Krabbe Disease Treatment Market Value, By Diagnosis, 2021-2030 ($ Million)

Table33 Europe Krabbe Disease Treatment Market Value, By Treatment, 2021-2030 ($ Million)

Table34 Europe Krabbe Disease Treatment Market Value, By End user, 2021-2030 ($ Million)

Table35 Europe Krabbe Disease Treatment Market Value, By Distribution Channel, 2021-2030 ($ Million)

Table36 Europe Krabbe Disease Treatment Market Value, By Country, 2021-2030 ($ Million)

Table37 Asia-Pacific Krabbe Disease Treatment Market Value, By Disease Type, 2021-2030 ($ Million)

Table38 Asia-Pacific Krabbe Disease Treatment Market Value, By Diagnosis, 2021-2030 ($ Million)

Table39 Asia-Pacific Krabbe Disease Treatment Market Value, By Treatment, 2021-2030 ($ Million)

Table40 Asia-Pacific Krabbe Disease Treatment Market Value, By End user, 2021-2030 ($ Million)

Table41 Asia-Pacific Krabbe Disease Treatment Market Value, By Distribution Channel, 2021-2030 ($ Million)

Table42 Asia-Pacific Krabbe Disease Treatment Market Value, By Country, 2021-2030 ($ Million)

Table43 Middle East &amp; Africa Krabbe Disease Treatment Market Value, By Disease Type, 2021-2030 ($ Million)

Table44 Middle East &amp; Africa Krabbe Disease Treatment Market Value, By Diagnosis, 2021-2030 ($ Million)

Table45 Middle East &amp; Africa Krabbe Disease Treatment Market Value, By Treatment, 2021-2030 ($ Million)

Table46 Middle East &amp; Africa Krabbe Disease Treatment Market Value, By End user, 2021-2030 ($ Million)

Table47 Middle East &amp; Africa Krabbe Disease Treatment Market Value, By Distribution Channel, 2021-2030 ($ Million)

Table48 Lannett: Overview

Table49 Lannett: Product Portfolio

Table50 Lannett: Key Developments

Table51 Novartis: Overview

Table52 Novartis: Product Portfolio

Table53 Novartis: Key Developments

Table54 Lundbeck: Overview

Table55 Lundbeck: Product Portfolio

Table56 Lundbeck: Key Developments

Table57 Lupin Pharmaceuticals, Inc.: Overview

Table58 Lupin Pharmaceuticals, Inc.: Product Portfolio

Table59 Lupin Pharmaceuticals, Inc.: Key Developments

Table60 Teva Pharmaceuticals USA, Inc.: Overview

Table61 Teva Pharmaceuticals USA, Inc.: Product Portfolio

Table62 Teva Pharmaceuticals USA, Inc.: Key Developments

Table63 Meda Pharmaceuticals Inc: Overview

Table64 Meda Pharmaceuticals Inc: Product Portfolio

Table65 Meda Pharmaceuticals Inc: Key Developments

Table66 Mayne Pharma Group Limited: Overview

Table67 Mayne Pharma Group Limited: Product Portfolio

Table68 Mayne Pharma Group Limited: Key Developments

Table69 Pfizer Inc.: Overview

Table70 Pfizer Inc.: Product Portfolio

Table71 Pfizer Inc.: Key Developments

Table72 Schwarz Pharma, Inc: Overview

Table73 Schwarz Pharma, Inc: Product Portfolio

Table74 Schwarz Pharma, Inc: Key Developments

Table75 Acorda Therapeutics Inc.: Overview

Table76 Acorda Therapeutics Inc.: Product Portfolio

Table77 Acorda Therapeutics Inc.: Key Developments

List of Figures

Figure1 Global Krabbe Disease Treatment Market Share, By Disease Type, 2022 &amp; 2030 (%)

Figure2 Global Krabbe Disease Treatment Market Share, By Diagnosis, 2022 &amp; 2030 (%)

Figure3 Global Krabbe Disease Treatment Market Share, By Treatment, 2022 &amp; 2030 (%)

Figure4 Global Krabbe Disease Treatment Market Share, By End user, 2022 &amp; 2030 (%)

Figure5 Global Krabbe Disease Treatment Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure6 Global Krabbe Disease Treatment Market Share, By Region, 2022 &amp; 2030 (%)

Figure7 Global Krabbe Disease Treatment Market Value, 2021-2030 ($ Million)

Figure8 Global Krabbe Disease Treatment Market Y-o-Y Growth, By Disease Type, 2022-2030 (%)

Figure9 Infantile: Global Krabbe Disease Treatment Market Value, 2021-2030 ($ Million)

Figure10 Late-onset: Global Krabbe Disease Treatment Market Value, 2021-2030 ($ Million)

Figure11 Global Krabbe Disease Treatment Market Y-o-Y Growth, By Diagnosis, 2022-2030 (%)

Figure12 Laboratory tests: Global Krabbe Disease Treatment Market Value, 2021-2030 ($ Million)

Figure13 Imaging tests: Global Krabbe Disease Treatment Market Value, 2021-2030 ($ Million)

Figure14 Genetic testing: Global Krabbe Disease Treatment Market Value, 2021-2030 ($ Million)

Figure15 Newborn screening: Global Krabbe Disease Treatment Market Value, 2021-2030 ($ Million)

Figure16 Others: Global Krabbe Disease Treatment Market Value, 2021-2030 ($ Million)

Figure17 Global Krabbe Disease Treatment Market Y-o-Y Growth, By Treatment, 2022-2030 (%)

Figure18 Anticonvulsant Agents: Global Krabbe Disease Treatment Market Value, 2021-2030 ($ Million)

Figure19 Muscle Relaxer Drugs: Global Krabbe Disease Treatment Market Value, 2021-2030 ($ Million)

Figure20 Bone Marrow Transplantation: Global Krabbe Disease Treatment Market Value, 2021-2030 ($ Million)

Figure21 Stem cell transplantation: Global Krabbe Disease Treatment Market Value, 2021-2030 ($ Million)

Figure22 Others: Global Krabbe Disease Treatment Market Value, 2021-2030 ($ Million)

Figure23 Global Krabbe Disease Treatment Market Y-o-Y Growth, By End user, 2022-2030 (%)

Figure24 Hospital: Global Krabbe Disease Treatment Market Value, 2021-2030 ($ Million)

Figure25 Diagnostic Centers: Global Krabbe Disease Treatment Market Value, 2021-2030 ($ Million)

Figure26 Clinics: Global Krabbe Disease Treatment Market Value, 2021-2030 ($ Million)

Figure27 Others: Global Krabbe Disease Treatment Market Value, 2021-2030 ($ Million)

Figure28 Global Krabbe Disease Treatment Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure29 Hospital Pharmacies: Global Krabbe Disease Treatment Market Value, 2021-2030 ($ Million)

Figure30 Retail Pharmacies: Global Krabbe Disease Treatment Market Value, 2021-2030 ($ Million)

Figure31 Online Pharmacies: Global Krabbe Disease Treatment Market Value, 2021-2030 ($ Million)

Figure32 Others: Global Krabbe Disease Treatment Market Value, 2021-2030 ($ Million)

Figure33 Global Krabbe Disease Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure34 North America Krabbe Disease Treatment Market Value, 2021-2030 ($ Million)

Figure35 North America Krabbe Disease Treatment Market Share, By Disease Type, 2022 &amp; 2030 (%)

Figure36 North America Krabbe Disease Treatment Market Share, By Diagnosis, 2022 &amp; 2030 (%)

Figure37 North America Krabbe Disease Treatment Market Share, By Treatment, 2022 &amp; 2030 (%)

Figure38 North America Krabbe Disease Treatment Market Share, By End user, 2022 &amp; 2030 (%)

Figure39 North America Krabbe Disease Treatment Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure40 North America Krabbe Disease Treatment Market Share, By Country, 2022 &amp; 2030 (%)

Figure41 South America Krabbe Disease Treatment Market Value, 2021-2030 ($ Million)

Figure42 South America Krabbe Disease Treatment Market Share, By Disease Type, 2022 &amp; 2030 (%)

Figure43 South America Krabbe Disease Treatment Market Share, By Diagnosis, 2022 &amp; 2030 (%)

Figure44 South America Krabbe Disease Treatment Market Share, By Treatment, 2022 &amp; 2030 (%)

Figure45 South America Krabbe Disease Treatment Market Share, By End user, 2022 &amp; 2030 (%)

Figure46 South America Krabbe Disease Treatment Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure47 South America Krabbe Disease Treatment Market Share, By Country, 2022 &amp; 2030 (%)

Figure48 Europe Krabbe Disease Treatment Market Value, 2021-2030 ($ Million)

Figure49 Europe Krabbe Disease Treatment Market Share, By Disease Type, 2022 &amp; 2030 (%)

Figure50 Europe Krabbe Disease Treatment Market Share, By Diagnosis, 2022 &amp; 2030 (%)

Figure51 Europe Krabbe Disease Treatment Market Share, By Treatment, 2022 &amp; 2030 (%)

Figure52 Europe Krabbe Disease Treatment Market Share, By End user, 2022 &amp; 2030 (%)

Figure53 Europe Krabbe Disease Treatment Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure54 Europe Krabbe Disease Treatment Market Share, By Country, 2022 &amp; 2030 (%)

Figure55 Asia-Pacific Krabbe Disease Treatment Market Value, 2021-2030 ($ Million)

Figure56 Asia-Pacific Krabbe Disease Treatment Market Share, By Disease Type, 2022 &amp; 2030 (%)

Figure57 Asia-Pacific Krabbe Disease Treatment Market Share, By Diagnosis, 2022 &amp; 2030 (%)

Figure58 Asia-Pacific Krabbe Disease Treatment Market Share, By Treatment, 2022 &amp; 2030 (%)

Figure59 Asia-Pacific Krabbe Disease Treatment Market Share, By End user, 2022 &amp; 2030 (%)

Figure60 Asia-Pacific Krabbe Disease Treatment Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure61 Asia-Pacific Krabbe Disease Treatment Market Share, By Country, 2022 &amp; 2030 (%)

Figure62 Middle East &amp; Africa Krabbe Disease Treatment Market Value, 2021-2030 ($ Million)

Figure63 Middle East &amp; Africa Krabbe Disease Treatment Market Share, By Disease Type, 2022 &amp; 2030 (%)

Figure64 Middle East &amp; Africa Krabbe Disease Treatment Market Share, By Diagnosis, 2022 &amp; 2030 (%)

Figure65 Middle East &amp; Africa Krabbe Disease Treatment Market Share, By Treatment, 2022 &amp; 2030 (%)

Figure66 Middle East &amp; Africa Krabbe Disease Treatment Market Share, By End user, 2022 &amp; 2030 (%)

Figure67 Middle East &amp; Africa Krabbe Disease Treatment Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure68 Lannett: Financials

Figure69 Novartis: Financials

Figure70 Lundbeck: Financials

Figure71 Lupin Pharmaceuticals, Inc.: Financials

Figure72 Teva Pharmaceuticals USA, Inc.: Financials

Figure73 Meda Pharmaceuticals Inc: Financials

Figure74 Mayne Pharma Group Limited: Financials

Figure75 Pfizer Inc.: Financials

Figure76 Schwarz Pharma, Inc: Financials

Figure77 Acorda Therapeutics Inc.: Financials